KRRO Korro Bio Inc.

Price (delayed)

$11.12

Market cap

$160.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.67

Enterprise value

$141.57M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the ...

Highlights
Korro Bio's debt has decreased by 5% YoY
Korro Bio's equity has soared by 133% from the previous quarter but it has decreased by 14% YoY
KRRO's net income is down by 30% year-on-year but it is up by 3.2% since the previous quarter
Korro Bio's revenue has decreased by 40% QoQ and by 20% YoY
Korro Bio's gross profit has decreased by 40% from the previous quarter and by 20% YoY

Key stats

What are the main financial stats of KRRO

KRRO stock price

How has the Korro Bio stock price performed over time
Intraday
0.36%
1 week
-17.01%
1 month
-14.66%
1 year
-6.4%
YTD
38.83%
QTD
-1.77%

Financial performance

How have Korro Bio's revenue and profit performed over time
Revenue
$3.84M
Gross profit
$3.84M
Operating income
-$117.27M
Net income
-$113.5M
Gross margin
100%
Net margin
-2,954.1%
Korro Bio's net margin has plunged by 63% YoY and by 61% from the previous quarter
KRRO's operating margin has shrunk by 60% QoQ and by 54% YoY
Korro Bio's revenue has decreased by 40% QoQ and by 20% YoY
Korro Bio's gross profit has decreased by 40% from the previous quarter and by 20% YoY

Price vs fundamentals

How does KRRO's price correlate with its fundamentals

Growth

What is Korro Bio's growth rate over time

Valuation

What is Korro Bio stock price valuation
P/E
N/A
P/B
1.34
P/S
33.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.85
KRRO's EPS is down by 24% YoY but it is up by 6% QoQ
Korro Bio's equity has soared by 133% from the previous quarter but it has decreased by 14% YoY
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 2.1 and 16% less than its 5-year quarterly average of 1.6
Korro Bio's revenue has decreased by 40% QoQ and by 20% YoY
The stock's price to sales (P/S) is 7% more than its last 4 quarters average of 31.4

Efficiency

How efficient is Korro Bio business performance
The return on equity has dropped by 128% year-on-year
KRRO's return on assets has dropped by 87% year-on-year
KRRO's ROS has shrunk by 62% YoY and by 61% QoQ
KRRO's ROIC has plunged by 60% YoY

Dividends

What is KRRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRRO.

Financial health

How did Korro Bio financials performed over time
The total assets is 187% greater than the total liabilities
The total assets has surged by 62% since the previous quarter but it has declined by 9% year-on-year
KRRO's quick ratio is up by 21% since the previous quarter but it is down by 15% year-on-year
Korro Bio's debt is 64% less than its equity
Korro Bio's equity has soared by 133% from the previous quarter but it has decreased by 14% YoY
KRRO's debt to equity has dropped by 58% since the previous quarter but it is up by 9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.